Bispecific Antibodies

© GettyImages/Image Source

Lilly and Merus set to collaborate on cancer therapies

By Jane Byrne

Loxo Oncology at Lilly, an R&D division of Eli Lilly and Co, and Merus, a Dutch clinical-stage oncology company, today announced a partnership to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers